Clinical trials: COVID19 Patients
Respiratory Infections, COVID-19
Volatile Organic Compounds Analysis by GC-MS for Diagnostic of Hospitalised Patients With Respiratory Infections Using Exhaled Breath
Emerging respiratory diseases represent a global threat. Viruses such as influenza and coronaviruses have been the main drivers of pandemics over the past century.
- Conditions
- Respiratory Infections, COVID-19, Influenza Virus Infection, Legionella Pneumophila Infections
- Trial name
- VORTEX-2 (NCT07352462)
- Testing
- Volatile Organic compounds (VOC) analysis in Exhaled breath using GC-MS
- Where
- 7 sites in France
- Volunteers
- 777 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Rehabilitation, Pneumonia, Viral
Rehabilitation Treatment of Patients With COVID-19
This is single centre retrospective study with propensity score matching. The aim of the study is to develop criteria for determining groups of patients with a new coronavirus infection based on clinical, laboratory and…
- Conditions
- Rehabilitation, Pneumonia, Viral, COVID-19, Quality of Life
- Trial name
- COVID-REHAB (NCT05808361)
- Testing
- exercises, massage
- Where
- Russia
- Volunteers
- 180 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
COVID-19, Immunodeficiency
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients
The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy direct antiviral agents (remdesivir + nirmatrelvir/r) versus the reference monotherapy (nirmatrelvir/r alone) and…
- Trial name
- SWISS OPTICOV (NCT07406217)
- Testing
- Paxlovid 5 days, Paxlovid 10 days
- Where
- 4 sites in Switzerland
- Volunteers
- 256 people
- Sponsor
- Calmy Alexandra
Multiple Myeloma, Waldenstrom Macroglobulinemia
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
This research is being done to see if the immune (defense) system of people with Multiple Myeloma and Waldenstrom's Macroglobulinemia reacts to the COVID-19 vaccine.
- Conditions
- Multiple Myeloma, Waldenstrom Macroglobulinemia, Immune System Disorder, Covid19
- Trial name
- NCT04830046
- Where
- 2 sites in United States
- Volunteers
- 146 people
- Sponsor
- Massachusetts General Hospital
Pulmonary Fibrosis, COVID-19 Pneumonia
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
The primary purpose of this study is to determine whether the drug sirolimus reduces the likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19 pneumonia.
- Conditions
- Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
- Trial name
- NCT04948203
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Chicago
Covid19, Organ Failure, Multiple
DNA Damage in Critically Ill COVID-19 Patients
Critically ill patients with COVID-19 are exposed to high oxidative stress which is potential harm to the DNA. Peripheral lymphocytes' DNA will be investigated using the comet assay on changes in oxidative damage to the purine…
- Conditions
- Covid19, Organ Failure, Multiple, DNA Damage
- Trial name
- NCT04772703
- Testing
- COMET ASSAY
- Where
- Czechia
- Volunteers
- 10 people
- Sponsor
- University Hospital Hradec Kralove
Covid19, Prostate Specific Antigen
Changing of Prostate Specific Antigen Value in Patients With Covid-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a worldwide pandemic in over 100 years. The disease caused by this newly discovered virus was called Covid-19.
- Trial name
- NCT05009186
- Testing
- PSA value
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Saglik Bilimleri Universitesi
Surgery, COVID
Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey
a brief questionnaire to get a clearer picture of the situation regarding surgical patients with special emphasis on asymptomatic Covid-19 patients.
- Conditions
- Surgery, COVID, Asymptomatic Patient, Covid-19
- Trial name
- NCT04344197
- Testing
- global survey
- Where
- Italy
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- University of Rome Tor Vergata
Sars-CoV2
Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19
Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia
- Trial name
- NCT04366323
- Testing
- ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
- Where
- 6 sites in Spain
- Volunteers
- 26 people
- Sponsor
- Andalusian Network for Design and Translation of Advanced Therapies
Pressure Ulcer, Respiratory Distress Syndrome, Acute
Extended Prone Position Duration COVID-19-related ARDS: a Retrospective Study
Prone position (PP) is standard of care for mechanically ventilated patients with severe acute respiratory distress syndrome in the intensive care unit (ICU). Recommendations suggest PP durations of at least 16 hours.
- Conditions
- Pressure Ulcer, Respiratory Distress Syndrome, Acute, Hypoxemic Respiratory Failure, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05124197
- Testing
- prone position
- Where
- France
- Volunteers
- 81 people
- Sponsor
- Hôpital Louis Mourier
Health Care Worker Patient Transmission, Receptor Site Alteration
Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19.
The primary objective of this study is to establish differences in susceptibility to SARS CoV-2 infection among health care workers (HCW) highly exposed to patients with COVID-19 diagnosis.
- Conditions
- Health Care Worker Patient Transmission, Receptor Site Alteration, Susceptibility, Disease, Immune Response
- Trial name
- CoVEX (NCT04402827)
- Testing
- Susceptibility to infection
- Where
- Spain
- Volunteers
- 140 people
- Sponsor
- Asociacion para el Estudio de las Enfermedades Infecciosas
COVID-19
Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19
This is a multicenter, double-blind, randomized, placebo-controlled, loaded Phase III clinical study. This test is in a new coronavirus infection pneumonia diagnosis and treatment plan of 9 (trial version) "(SoC), on the basis of…
- Trial name
- NCT05679479
- Testing
- Meplazumab for injection, Normal saline
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
COVID-19, SARS-CoV2 Infection
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT05593770)
- Testing
- Fostamatinib
- Where
- 21 sites in Brazil, Germany and 3 more
- Volunteers
- 28 people
- Sponsor
- NEAT ID Foundation
COVID-19 (SARS-CoV-2 Infection)
Study on the Performance and Safety of Sentinox in COVID-19 Patients
This is a single-center, randomized, controlled, open-label, pilot study to assess the safety and the performance of Sentinox medical device in the treatment of mild COVID-19 patients. The study will consist of 9 visits.
- Trial name
- NCT04909996
- Testing
- Sentinox--Group A, Sentinox--Group B
- Where
- Italy
- Volunteers
- 57 people
- Sponsor
- APR Applied Pharma Research s.a.
Infection Viral, Infection, Hospital
Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF
The COVID-19 pandemic of SARS CoV2 (Severe Acute Respiratory Syndrome, COVID-19) infection, which is currently evolving in France, raises many questions about the clinical and biological profile of infected hospitalized patients.
- Conditions
- Infection Viral, Infection, Hospital, COVID
- Trial name
- CCF (NCT04344327)
- Where
- 23 sites in France
- Volunteers
- 2,878 people
- Sponsor
- French Cardiology Society
COVID-19 Patients, Hypoxemic Respiratory Failure
Awake Prone Positioning in COVID-19 Suspects With Hypoxemic Respiratory Failure
The investigator hypothesis is that early implementation of early, awake prone position for patients with COVID-19 pneumonia requiring oxygen therapy will reduce the need for escalation of respiratory support.
- Conditions
- COVID-19 Patients, Hypoxemic Respiratory Failure, Prone Position
- Trial name
- NCT04853979
- Testing
- PRONE POSITION
- Where
- Qatar
- Volunteers
- 61 people
- Sponsor
- Hamad Medical Corporation
Sars-CoV-2 Infection
A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19
The innovative drug XC221 100 mg tablet is designed for the treatment of COVID-19 (SARS-CoV-2 infection). A multicenter, adaptive, randomized, double-blind, placebo-controlled Phase III clinical study is aimed to assess the…
- Trial name
- NCT04940182
- Testing
- XC221
- Where
- 11 sites in Russia
- Volunteers
- 274 people
- Sponsor
- RSV Therapeutics LLC
COVID-19, Long COVID
CORona (COVID-19) Follow Up Study: Epidemiology, Pathophysiology, Prediction, and Communication
The CORFU study, funded by ZonMW, is a prospective, multiple, cohort study with a maximum follow-up of 24 months after COVID-19.
- Conditions
- COVID-19, Long COVID, Post COVID-19 Condition
- Trial name
- CORFU (NCT05240742)
- Testing
- no intervention, the CORFU study conducts analyses based on data which has been prospectively collected (and aggregated when possible) in 7 existing cohorts
- Where
- Netherlands
- Volunteers
- 4,291 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Covid-19 Infection
Awake Pronation for Covid-19 Treatment
Observational studies have shown that prone position (PP) in spontaneously breathing patients, may improve oxygenation in individuals with Acute Respiratory Failure (ARF), due to Covid-19 infection.
- Trial name
- NCT04667286
- Testing
- Prone Position (PP)
- Where
- 3 sites in Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Covid19, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients
There is currently no known treatment for COVID19. Active smokers are infrequent among patients with COVID-19 which has led our team to hypothesize that nicotine is responsible for this protective effect via the nicotinic…
- Trial name
- NICOVID-REA (NCT04598594)
- Testing
- Patch, Nicotine
- Where
- 18 sites in France
- Volunteers
- 220 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.